» Articles » PMID: 29721199

Rapid Methods to Create a Positive Control and Identify the Rearrangement in FNA Thyroid Samples by Molecular Biology

Overview
Journal Oncotarget
Specialty Oncology
Date 2018 May 4
PMID 29721199
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is the most common malignancy of the endocrine system and includes well-differentiated forms, namely papillary and follicular carcinomas, and the poorly differentiated and undifferentiated forms that result from the transformation of thyroid follicular cells (anaplastic carcinomas). Notably, 5-10% of all thyroid cancers are medullary thyroid cancers that arise from parafollicular cells also known as C cells. The most common genetic mutations in papillary and follicular thyroid cancers are point mutations of the or genes, while the most common chromosomal alterations are and rearrangements. The most frequent initial manifestation of thyroid cancer is the appearance of a nodule most of which are benign; indeed, less than 5% are malignant. However, some cases are misdiagnosed, and many patients undergo unnecessary surgery. Therefore, an accurate pre-surgery evaluation is crucial. The most reliable diagnostic test for thyroid nodules is fine needle aspiration (FNA) cytology, which accurately distinguishes between a benign and malignant lesion in most cases. However, cytological discrimination between malignant and benign follicular cancer is often difficult because of poor quality samples. Here we describe rapid methods to create a positive control and identify the rearrangement in FNA thyroid samples by molecular biology.

Citing Articles

Web-based prediction models for predicting overall survival and cancer specific survival in lung metastasis of patients with thyroid cancer: a study based on the SEER database and a Chinese cohort.

Yin F, Wang S, Jiang Z, Tong Y, Han L, Sun W J Cancer. 2024; 15(20):6768-6783.

PMID: 39668837 PMC: 11632997. DOI: 10.7150/jca.103542.


In Silico Search for Drug Candidates Targeting the PAX8-PPARγ Fusion Protein in Thyroid Cancer.

Sakaguchi K, Okiyama Y, Tanaka S Int J Mol Sci. 2024; 25(10).

PMID: 38791384 PMC: 11121424. DOI: 10.3390/ijms25105347.


In silico modeling of PAX8-PPARγ fusion protein in thyroid carcinoma: influence of structural perturbation by fusion on ligand-binding affinity.

Sakaguchi K, Okiyama Y, Tanaka S J Comput Aided Mol Des. 2021; 35(5):629-642.

PMID: 33748935 DOI: 10.1007/s10822-021-00381-x.


Impact of ultrasonographic features, cytomorphology and mutational testing on malignant and indeterminate thyroid nodules on diagnostic accuracy of fine needle cytology samples: A prospective analysis of 141 patients.

Fulciniti F, Cipolletta Campanile A, Malzone M, Chiofalo M, Capiluongo A, Monaco M Clin Endocrinol (Oxf). 2019; 91(6):851-859.

PMID: 31483883 PMC: 6972562. DOI: 10.1111/cen.14089.

References
1.
Algeciras-Schimnich A, Milosevic D, McIver B, Flynn H, Reddi H, Eberhardt N . Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. Clin Chem. 2010; 56(3):391-8. PMC: 3918957. DOI: 10.1373/clinchem.2009.134015. View

2.
Ciampi R, Nikiforov Y . RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2006; 148(3):936-41. DOI: 10.1210/en.2006-0921. View

3.
Marques A, Espadinha C, Catarino A, Moniz S, Pereira T, Sobrinho L . Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002; 87(8):3947-52. DOI: 10.1210/jcem.87.8.8756. View

4.
Placzkowski K, Reddi H, Grebe S, Eberhardt N, McIver B . The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. PPAR Res. 2008; 2008:672829. PMC: 2579323. DOI: 10.1155/2008/672829. View

5.
Sherman S . Thyroid carcinoma. Lancet. 2003; 361(9356):501-11. DOI: 10.1016/s0140-6736(03)12488-9. View